Routine Tax Settlement: ADMA Insider Still Holds Nearly Half-Million Shares
Rhea-AI Filing Summary
ADMA Biologics COO & SVP, Compliance Kaitlin M. Kestenberg-Messina filed a Form 4 for an automatic share withholding event on 07/24/2025. Transaction code F shows 3,027 common shares were surrendered to the company at $17.31 per share to satisfy payroll-tax obligations triggered by the vesting of restricted stock units (RSUs); no shares were sold on the open market.
Post-transaction, the executive beneficially owns 487,398 ADMA shares, comprised of 192,874 fully vested shares and 294,524 unvested RSUs that vest quarterly through 2029, contingent on continued service.
- The filing is a routine tax-settlement and does not reflect a discretionary reduction in ownership.
- Share count outstanding is modestly reduced, but insider economic exposure is unchanged.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine RSU tax withholding; neutral signal, insider keeps sizable stake.
The code F transaction merely covers withholding taxes on vested RSUs and does not indicate an intentional sale. Only 3,027 shares (≈0.6% of her total holdings) left the insider’s account, while 487k shares remain beneficially owned. Such filings are common and usually carry no market-moving information. Investors should focus instead on upcoming fundamentals (e.g., immunoglobulin demand and margin expansion) rather than this administrative entry.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 3,027 | $17.31 | $52K |
Footnotes (1)
- Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 144,240 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 15,000 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (continued from footnote 2) (iv) 47,500 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (v) 10,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vi) 192,874 shares of common stock directly owned by the reporting person, which includes the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
